E2F3 and gastric adenocarcinoma: Evaluation of gene expression across pathological stages of STAD revealed an increasing trend of COL4A1 expression with disease progression, reaching statistical significance between stage I and stage IV (P = 0.048), whereas THBS2, CTNNB1, and E2F3 showed no significant stage-dependent variation (Fig. 2 C).